Nyrada Inc - Asset Resilience Ratio

Latest as of June 2025: 55.29%

Nyrada Inc (NYR) has an Asset Resilience Ratio of 55.29% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check asset allocation strategy of Nyrada Inc to assess the company's strategic physical and investment asset allocation.

Liquid Assets

AU$2.93 Million
≈ $2.07 Million USD Cash + Short-term Investments

Total Assets

AU$5.30 Million
≈ $3.75 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2021–2022)

This chart shows how Nyrada Inc's Asset Resilience Ratio has changed over time. See Nyrada Inc (NYR) net asset quality to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Nyrada Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see NYR market cap overview.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$2.93 Million 55.29%
Short-term Investments AU$0.00 0%
Total Liquid Assets AU$2.93 Million 55.29%

Asset Resilience Insights

  • Very High Liquidity: Nyrada Inc maintains exceptional liquid asset reserves at 55.29% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Nyrada Inc Industry Peers by Asset Resilience Ratio

Compare Nyrada Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Revolution Medicines Inc
NASDAQ:RVMD
Biotechnology 65.10%
Tubize-Fin
BR:TUB
Biotechnology 0.05%
Hugel Inc
KQ:145020
Biotechnology 29.57%
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
Biotechnology 39.07%
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
Biotechnology 2.30%
Absci Corp
NASDAQ:ABSI
Biotechnology 59.86%
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
Biotechnology 5.52%
Lifecome Biochemistry Co Ltd
SHE:002868
Biotechnology 4.69%

Annual Asset Resilience Ratio for Nyrada Inc (2021–2022)

The table below shows the annual Asset Resilience Ratio data for Nyrada Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2022-06-30 90.03% AU$10.82 Million
≈ $7.65 Million
AU$12.01 Million
≈ $8.50 Million
-0.70pp
2021-06-30 90.72% AU$13.75 Million
≈ $9.73 Million
AU$15.16 Million
≈ $10.72 Million
--
pp = percentage points

About Nyrada Inc

AU:NYR Australia Biotechnology
Market Cap
$80.59 Million
AU$113.90 Million AUD
Market Cap Rank
#20103 Global
#663 in Australia
Share Price
AU$0.47
Change (1 day)
+0.00%
52-Week Range
AU$0.22 - AU$1.38
All Time High
AU$1.38
About

Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases. Its lead candidate is Xolatryp, a small molecule drug which has completed phase 1 clinical trial for neuroprotection and cardioprotection indications and in patients with traumatic brain injury and ischaemic stroke. Nyrada Inc. was incorporat… Read more